IPO registrations (S-1, F-1) · Registrants
TuHURA Biosciences, Inc./NV
- SEC CIK
- 1498382 · filings on EDGAR ↗
- Former names
- Kintara Therapeutics, Inc. (2020–2024); DelMar Pharmaceuticals, Inc. (2013–2020); Berry Only Inc. (2010–2013)
- Registration
- Form S-1, first filed 2010-08-17, last 2025-09-18; 8 initial registrations, 21 amendments
- Outcome
- Final prospectus filed 2019-05-29; declared effective 2010-12-22; withdrawal requested 2019-06-27
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 10500 UNIVERSITY CENTER DR., SUITE 110, Tampa, FL 33612
- EIN
- 99-0360497
- Ticker
- HURA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- TuHURA Biosciences, Inc./NV on the corporate pages
On this site
- Business registration: TUHURA BIOSCIENCES, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form D issuer: TuHURA Biosciences, Inc./NV EXACT (CIK (EXACT))
- SEC filer: DelMar Pharmaceuticals, Inc. EXACT (CIK (EXACT))
Filings 60
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2010-08-17 | S-1 | S-1 (registration) | Berry Only Inc. | 0001127855-10-000330 ↗ |
| 2010-09-23 | S-1/A | S-1/A (amendment) | Berry Only Inc. | 0001127855-10-000365 ↗ |
| 2010-10-15 | S-1/A | S-1/A (amendment) | Berry Only Inc. | 0001127855-10-000396 ↗ |
| 2010-11-12 | S-1/A | S-1/A (amendment) | Berry Only Inc. | 0001127855-10-000415 ↗ |
| 2010-12-02 | S-1/A | S-1/A (amendment) | Berry Only Inc. | 0001127855-10-000443 ↗ |
| 2010-12-22 | EFFECT | EFFECT (declared effective) | Berry Only Inc. | 9999999995-10-003673 ↗ |
| 2013-06-14 | S-1 | S-1 (registration) | DelMar Pharmaceuticals, Inc. | 0001013762-13-000818 ↗ |
| 2013-06-28 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-13-001965 ↗ |
| 2014-04-29 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-14-001158 ↗ |
| 2015-03-13 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-15-000600 ↗ |
| 2015-04-10 | S-1 | S-1 (registration) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000333 ↗ |
| 2015-04-21 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000381 ↗ |
| 2015-05-07 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000441 ↗ |
| 2015-05-12 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000456 ↗ |
| 2015-05-12 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000464 ↗ |
| 2015-05-14 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000470 ↗ |
| 2015-06-12 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000625 ↗ |
| 2015-06-23 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000643 ↗ |
| 2015-06-30 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000664 ↗ |
| 2015-07-09 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000701 ↗ |
| 2015-07-15 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001013762-15-000714 ↗ |
| 2015-07-15 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-15-001921 ↗ |
| 2015-11-30 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-15-003153 ↗ |
| 2016-09-21 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-16-005734 ↗ |
| 2016-09-27 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-16-005799 ↗ |
| 2016-09-27 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-16-005800 ↗ |
| 2019-02-19 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-19-000296 ↗ |
| 2019-04-18 | S-1 | S-1 (registration) | DelMar Pharmaceuticals, Inc. | 0001213900-19-006641 ↗ |
| 2019-05-08 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001213900-19-007997 ↗ |
| 2019-05-23 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001213900-19-009520 ↗ |
| 2019-05-28 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-19-001213 ↗ |
| 2019-05-29 | 424B4 | 424B4 (final prospectus) | DelMar Pharmaceuticals, Inc. | 0001213900-19-009684 ↗ |
| 2019-05-30 | 424B4 | 424B4 (final prospectus) | DelMar Pharmaceuticals, Inc. | 0001213900-19-009811 ↗ |
| 2019-06-25 | S-1 | S-1 (registration) | DelMar Pharmaceuticals, Inc. | 0001213900-19-011448 ↗ |
| 2019-06-27 | RW | RW (withdrawal request) | DelMar Pharmaceuticals, Inc. | 0001213900-19-011643 ↗ |
| 2019-07-11 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001213900-19-012524 ↗ |
| 2019-07-16 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-19-001616 ↗ |
| 2019-07-17 | 424B4 | 424B4 (final prospectus) | DelMar Pharmaceuticals, Inc. | 0001213900-19-012915 ↗ |
| 2019-08-01 | S-1 | S-1 (registration) | DelMar Pharmaceuticals, Inc. | 0001213900-19-014256 ↗ |
| 2019-08-12 | S-1/A | S-1/A (amendment) | DelMar Pharmaceuticals, Inc. | 0001213900-19-015377 ↗ |
| 2019-08-14 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-19-001880 ↗ |
| 2019-08-15 | 424B4 | 424B4 (final prospectus) | DelMar Pharmaceuticals, Inc. | 0001213900-19-015963 ↗ |
| 2019-11-20 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-19-002617 ↗ |
| 2019-11-20 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-19-002618 ↗ |
| 2019-11-21 | 424B4 | 424B4 (final prospectus) | DelMar Pharmaceuticals, Inc. | 0001213900-19-024249 ↗ |
| 2019-11-21 | 424B4 | 424B4 (final prospectus) | DelMar Pharmaceuticals, Inc. | 0001213900-19-024251 ↗ |
| 2020-07-02 | EFFECT | EFFECT (declared effective) | DelMar Pharmaceuticals, Inc. | 9999999995-20-001631 ↗ |
| 2020-11-04 | 424B4 | 424B4 (final prospectus) | Kintara Therapeutics, Inc. | 0001564590-20-050543 ↗ |
| 2020-11-04 | EFFECT | EFFECT (declared effective) | Kintara Therapeutics, Inc. | 9999999995-20-003083 ↗ |
| 2021-04-01 | EFFECT | EFFECT (declared effective) | Kintara Therapeutics, Inc. | 9999999995-21-001258 ↗ |
| 2023-10-04 | S-1 | S-1 (registration) | Kintara Therapeutics, Inc. | 0000950170-23-051922 ↗ |
| 2023-10-24 | S-1/A | S-1/A (amendment) | Kintara Therapeutics, Inc. | 0000950170-23-054903 ↗ |
| 2023-10-27 | S-1/A | S-1/A (amendment) | Kintara Therapeutics, Inc. | 0000950170-23-055977 ↗ |
| 2024-03-13 | RW | RW (withdrawal request) | Kintara Therapeutics, Inc. | 0001193125-24-066370 ↗ |
| 2024-08-13 | EFFECT | EFFECT (declared effective) | Kintara Therapeutics, Inc. | 9999999995-24-002516 ↗ |
| 2024-10-15 | EFFECT | EFFECT (declared effective) | Kintara Therapeutics, Inc. | 9999999995-24-003183 ↗ |
| 2025-05-14 | EFFECT | EFFECT (declared effective) | TuHURA Biosciences, Inc./NV | 9999999995-25-001589 ↗ |
| 2025-08-12 | S-1 | S-1 (registration) | TuHURA Biosciences, Inc./NV | 0001193125-25-179009 ↗ |
| 2025-09-18 | S-1/A | S-1/A (amendment) | TuHURA Biosciences, Inc./NV | 0001193125-25-207395 ↗ |
| 2025-09-26 | EFFECT | EFFECT (declared effective) | TuHURA Biosciences, Inc./NV | 9999999995-25-003114 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bahouth Donald G. | TenPercentOwner | 1 | 2013 | ||
| Vollintine Raymond L. | TenPercentOwner | 1 | 2013 | ||
| FUGUET HOWARD K | TenPercentOwner | 1 | 2013 | ||
| Praill Anthony Scott | Officer | CFO; Chief Financial Officer; Chief Financial Officer | 36 | 2013–2022 | |
| BACHA JEFFREY | Director; Director,Officer; Director,Officer,TenPercentOwner; Officer,TenPercentOwner | CEO; CEO and President; CEO and PRESIDENT; CEO, Director; Chief Executive Officer; President, CEO | 32 | 2013–2018 | |
| Brown Dennis M | Director,Officer; Director,Officer,TenPercentOwner; Officer | Chief Scientifc Officer; Chief Scientific Officer | 40 | 2013–2023 | |
| Garner William J | Director | 9 | 2013–2015 | ||
| Bell John K | Director | 38 | 2013–2020 | ||
| TOTH ROBERT JOSEPH JR | Director | 35 | 2013–2023 | ||
| Cranston Lynda Sarah | Director | 24 | 2015–2020 | ||
| Mohr Erich | Director | 12 | 2015–2018 | ||
| Zarrabian Saiid | Director; Director,Officer | Head of Strategic Partnerships; Interim CEO; President and CEO | 10 | 2017–2021 | |
| HOFFMAN ROBERT | Director; Director,Officer | President and CEO; President, CEO, and CFO; President, CEO and Interim CFO | 15 | 2018–2026 | |
| Ferrara Napoleone | Director | 6 | 2018–2020 | ||
| Johnson Laura L. | Director | 6 | 2020–2023 | ||
| Liatos John | Director,Officer | SVP, Business Development | 3 | 2020 | |
| Murphy Keith | Director | 4 | 2020–2021 | ||
| FAVORITO TAMARA A | Director | 5 | 2021–2023 | ||
| Bianco James A. | Director,Officer | Chief Executive Officer | 6 | 2024–2026 | |
| Dearborn Dan | Officer | Chief Financial Officer | 5 | 2024–2026 | |
| List Alan | Director | 4 | 2024–2026 | ||
| MANUSO JAMES S J | Director | 4 | 2024–2026 | ||
| Ng George K | Director | 4 | 2024–2026 | ||
| Patel Vijay | TenPercentOwner | 1 | 2024 | ||
| Yamashita Dennis | Officer | Chief Scientific Officer | 2 | 2024 | |
| Tendler Craig | Director | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-11-10 | TuHURA Biosciences, Inc./NV | Biotechnology | $3,000,000 | $1,500,000 | 1 | 1 |
| 2025-06-13 | TuHURA Biosciences, Inc./NV | Biotechnology | $12,612,120 | $2,228,043 | 36 | 1 |
| 2020-08-28 | Kintara Therapeutics, Inc. | Pharmaceuticals | $30,000,000 | $21,772,000 | 161 | 1 |
| 2020-08-27 | Kintara Therapeutics, Inc. | Pharmaceuticals | $30,000,000 | $21,772,000 | 161 | 1 |
| 2016-05-10 | DelMar Pharmaceuticals, Inc. | Pharmaceuticals | Indefinite | $5,600,000 | 85 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.